Understanding the Monoclonal Antibody involvement in Targeting the Activation of Tumor Suppressor Genes.

Understanding the Monoclonal Antibody involvement in Targeting the Activation of Tumor Suppressor Genes. Curr Top Med Chem. 2020 Jun 16;: Authors: Mishra RK, Ahmad A, Vyawahare A, Kumar A, Khan R Abstract Monoclonal antibodies (mAbs) have always provided outstanding therapeutic arsenal in the treatment of cancer, be it hematological malignancies or solid tumors. Monoclonal antibodies mediated targeting of cancer genes in general and tumor-suppressor genes in particular have appreciably allowed the possibilities of trafficking these antibodies to specific tumor mechanisms and aim for the pin-pointly maneuvered tumor treatment strategies. The conventional cancer treatment options are associated with enormous limitations like drug resistance, acute and pan-toxic side effects and collateral damage to other unrelated cells and organs. Therefore monoclonal antibody mediated treatments have the special advantages of specific targeting of cancer related genes and minimizing the off-target side effects. Large number of monoclonal antibody mediated treatment regimen viz. use of immunoconjugates, clinically targeting TGFβ with pan-TGFβ monoclonal antibodies, p53 by its monoclonal antibodies and EGFR-targeted monoclonal antibodies etc. have been observed in the recent past. In this review, the authors have discussed some of the significant advances in the context of targeting tumor suppressor genes with monoclonal antibodies. Approximately 250...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research